Activation of the PI3K/AKT/mTOR pathway contributes to cancer progression and therapeutic resistance. Preclinical and early clinical data have suggested that dual targeting of HDAC and mTOR may have synergistic activity in treatment-refractory Hodgkin lymphoma. To explore this hypothesis, Janku and colleagues designed a phase I study combining vorinostat, an HDAC inhibitor, with sirolimus or everolimus, mTOR inhibitors, in patients with relapsed/refractory Hodgkin lymphoma. These combinations showed promising clinical efficacy, with an objective response rate of 55% and 33% in patients treated with vorinostat plus sirolimus and vorinostat plus everolimus, respectively. These results provide rationale for future investigation in Hodgkin lymphoma.
Immune biomarkers remain lacking to predict response to immunotherap. in ovarian cancer. Da Silva and colleagues performed a phase I clinical trial (GOG-9929) assessing adjuvant immune modulation therapy with the checkpoint inhibitor ipilimumab (anti-CTLA4) following chemoradiation therapy (CRT) in women with newly diagnosed node-positive human papillomavirus-related cervical cancer. In these...